Retroperitoneal, pleuropulmonary, and endocardial fibroses are relatively uncommon but serious side effects of the prophylactic antimigraine drug methysergide.1 2 Ergotamine is a potent drug in the treatment of the migraine attack, and is chemically related to methysergide. Retroperitoneal fibrosis has been reported in ergotamine users3-' and recently the occurrence of pleuropulmonary fibrosis with ergotamine was described.6 In the case reported here a causal relationship between the long-term use of ergotamine and the occurrence of pleuropulmonary fibrosis appears highly probable.
in weight over a period of six months. He had smoked 20 cigarettes a day, but he no longer enjoyed smoking. In January 1976 a chest radiograph taken during population screening for tuberculosis showed grossly pathological features of the lungs and pleura, and he was admitted to hospital.
On examination the patient appeared well and was not dyspnoeic. His blood pressure was 130/80 mm Hg and pulse rate 52 per minute, with sinus bradycardia on the electrocardiogram. The chest showed a decreased excursion on the right with no movement of the diaphragm on percussion. The resonance to percussion was decreased over the lower lobe with decreased tactile fremitus, decreased breath sounds, and a crackling friction rub. The heart sounds were normal.
Laboratory studies showed a considerably increased erythrocyte sedimentation rate of 118 mm in one hour, a reduced haemoglobin concentration of 8.3 g/dl, a normal white cell count of 8*5 x 109/l, and a normal eosinophil count of 0-127 x 109/1. The serum alkaline phosphatase level was 82 U/I (upper limit of normal 45 U/1) and yglutamyl transpeptidase 68 U/l (upper limit of normal 25 U/l), while the serum transaminase levels were normal. The serum protein concentration was 82 g/l (albumin 36 g/l and y-globulin 17 g/l). The serum IgM concentration was within the normal range, but the IgG was increased to 20-9 g/l (upper limit of normal 18 g/l). Antinuclear The mechanism by which methysergide and ergotamine might cause fibrosis is not clear. Because the effect cannot be reproduced in animals it has been suggested that the lesions might be due to an idiosyncratic or hypersensitivity reaction.7 Such a reaction, however, would be dose independent, whereas the fibrosis in patients using ergotamine has been reported almost exclusively after chronic and excessive use.
Another possible explanation for the fibrosis is prolonged vasoconstriction in relatively poorly vascularised tissues.8 Methysergide is a weaker vasoconstrictive agent than is ergotamine.9 An effect in which ergotamine and methysergide seem to be equally potent is that of potentiating serotonin-induced effects.'0 Serotonin from carcinoid tumours has been suggested as a cause of fibrosis.
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